🦴 Rheumatology News

Pfizer's brepocitinib (TYK2/JAK1 dual inhibitor) receives FDA approval for adult dermatomyositis after meeting its primary TIS endpoint and all 9 secondary endpoints in the VALOR trial — including muscle strength, skin disease, and functional status. It is the first oral therapy approved for any inflammatory myopathy. The mechanism targets type I interferon and IL-12/23 signaling directly, addressing the core immunopathology of dermatomyositis.

The Phase 3b BE BOLD trial shows bimekizumab (dual IL-17A/F blockade) achieves ACR50 in 49.1% versus 38.4% with risankizumab (IL-23 p19 inhibition) at 16 weeks — the first head-to-head superiority result on a joint endpoint in psoriatic arthritis. The mechanism advantage: blocking IL-17F as well as IL-17A provides more complete synovial suppression.